4/18
09:11 am
imnn
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 [Yahoo! Finance]
High
Report
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 [Yahoo! Finance]
4/18
08:30 am
imnn
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
Medium
Report
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
4/12
10:49 am
imnn
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine… [Yahoo! Finance]
Medium
Report
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine… [Yahoo! Finance]
4/11
08:14 am
imnn
IMUNON Reports Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
Low
Report
IMUNON Reports Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
4/11
08:00 am
imnn
IMUNON Reports Compliance with Nasdaq Listing Requirements
Low
Report
IMUNON Reports Compliance with Nasdaq Listing Requirements
4/1
07:13 pm
imnn
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/1
08:08 am
imnn
Imunon, Inc. (NASDAQ: IMNN) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.
High
Report
Imunon, Inc. (NASDAQ: IMNN) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.
3/28
08:09 am
imnn
IMUNON Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
IMUNON Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/28
08:00 am
imnn
IMUNON Reports 2023 Financial Results and Provides Business Update
Medium
Report
IMUNON Reports 2023 Financial Results and Provides Business Update
3/25
08:44 am
imnn
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses [Yahoo! Finance]
Medium
Report
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses [Yahoo! Finance]
3/25
08:30 am
imnn
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
Neutral
Report
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
3/21
05:07 pm
imnn
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 [Yahoo! Finance]
Medium
Report
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 [Yahoo! Finance]
3/21
05:00 pm
imnn
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
Medium
Report
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
3/18
03:11 pm
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/13
08:12 am
imnn
IMUNON Files IND Application to Begin Human Testing of IMNN-101 [Yahoo! Finance]
High
Report
IMUNON Files IND Application to Begin Human Testing of IMNN-101 [Yahoo! Finance]
3/13
08:00 am
imnn
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Medium
Report
IMUNON Files IND Application to Begin Human Testing of IMNN-101
3/12
05:18 pm
imnn
IMUNON Announces Leadership Change [Yahoo! Finance]
Medium
Report
IMUNON Announces Leadership Change [Yahoo! Finance]
3/12
05:00 pm
imnn
IMUNON Announces Leadership Change
High
Report
IMUNON Announces Leadership Change
2/29
12:40 pm
imnn
IMUNON stock rallies 19% on early results for COVID-19 vaccine [Seeking Alpha]
Medium
Report
IMUNON stock rallies 19% on early results for COVID-19 vaccine [Seeking Alpha]
2/29
08:40 am
imnn
Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 [Yahoo! Finance]
High
Report
Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 [Yahoo! Finance]
2/29
08:30 am
imnn
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
High
Report
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
2/27
08:43 am
imnn
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer [Yahoo! Finance]
High
Report
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer [Yahoo! Finance]
2/27
08:30 am
imnn
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
High
Report
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
2/22
08:09 am
imnn
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine [Yahoo! Finance]
Low
Report
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine [Yahoo! Finance]
2/22
08:00 am
imnn
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Low
Report
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine